RT Journal Article
SR Electronic
T1 Impaired HA-specific T follicular helper cell and antibody responses to influenza vaccination are linked to inflammation in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.07.21255038
DO 10.1101/2021.04.07.21255038
A1 Danika L Hill
A1 Silvia Innocentin
A1 Jiong Wang
A1 Eddie A James
A1 James C Lee
A1 William W Kwok
A1 Martin Zand
A1 Edward J Carr
A1 Michelle A Linterman
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.07.21255038.abstract
AB Antibody production following vaccination can provide protective immunity to subsequent infection from pathogens such as influenza. However, circumstances where antibody formation is impaired after vaccination, such as in older people, require us to better understand the cellular and molecular mechanisms that underpin successful vaccination in order to improve vaccine design for at risk groups. Here, by studying the breadth of anti-hemagglutinin (HA) IgG, serum cytokines, and B and T cell responses by flow cytometry before and after influenza vaccination, we show that formation of circulating T follicular helper cells (cTfh) cells are the best predictor of high titre antibody responses. Using MHC class II tetramers we demonstrate that HA-specific cTfh cells can derived from pre-existing memory CD4+ T cells and have a diverse TCR repertoire. In older people, the differentiation of HA-specific cells into cTfh cells was impaired. This age-dependent defect in cTfh cell formation was not due to a contraction of the TCR repertoire, but rather was linked with an increased inflammatory gene signature in cTfh cells. Together this suggests that strategies that temporarily dampen inflammation at the time of vaccination may be a viable strategy to boost optimal antibody generation upon immunisation of older people.One sentence summary Antibody production upon vaccination requires antigen-specific cTfh cells whose formation is suppressed by pro-inflammatory cytokine signalling.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by H2020 European Research Council funding awarded to MAL (637801-TWILIGHT) and the Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0427, BBS/E/B/000C0428, and the Campus Capability Core Grant to the Babraham Institute). DLH is supported by a National Health and Medical Research Council Australia Early-Career Fellowship (APP1139911). JCL is supported by a Wellcome Trust Intermediate Clinical Fellowship (105920/Z/14/Z). MAL is an EMBO Young Investigator and Lister Institute Prize Fellow. This paper presents independent research supported by the NIHR Cambridge BRC. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human blood and tissue were collected in accordance with the latest revision of the Declaration of Helsinki and the Guidelines for Good Clinical Practice (ICH-GCP). Ethical approval for all cohorts or sample collection was granted from the UK National Health Service Health Research Authority (NHS HRA) for the Research Ethics Committee (REC) references listed below. The seasonal UK influenza vaccination cohort (REC reference 14/SC/1077) was collected using the facilities and volunteer databases of Cambridge Bioresource (REC reference 04/Q0108/44). Lymph node samples were collected from UK adults undergoing surgery for their own medical care at Cambridge University Hospitals and processed at the Babraham Institute (REC reference 11/EE/0355). Approval was also granted for all included research from the Babraham Institute Human Ethics Committee. Written informed consent was received from all volunteers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.